{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:14:39Z","timestamp":1780938879075,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"grants-in-aid for scientific research","doi-asserted-by":"crossref","award":["19K07434"],"award-info":[{"award-number":["19K07434"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00428-021-03239-7","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T05:04:28Z","timestamp":1638162268000},"page":"621-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinicopathological significance of claspin overexpression and its efficacy as a novel biomarker for the diagnosis of urothelial carcinoma"],"prefix":"10.1007","volume":"480","author":[{"given":"Go","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsutaro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-5414","authenticated-orcid":false,"given":"Kazuhiro","family":"Sentani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Babasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Uraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Hanamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohide","family":"Oue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"3239_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, Palou J, Shariat SF (2018) European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73:111\u2013122. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036","journal-title":"Eur Urol"},{"key":"3239_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000126","volume":"1","author":"JJ Leow","year":"2016","unstructured":"Leow JJ, Chong KT, Chang SL, Bellmunt J (2016) Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open 1:e000126. https:\/\/doi.org\/10.1136\/esmoopen-2016-000126","journal-title":"ESMO Open"},{"key":"3239_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.urology.2010.04.020","volume":"76","author":"R Abouassaly","year":"2010","unstructured":"Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A (2010) Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 76:895\u2013901. https:\/\/doi.org\/10.1016\/j.urology.2010.04.020","journal-title":"Urology"},{"key":"3239_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.urology.2009.10.004","volume":"75","author":"C Jeldres","year":"2010","unstructured":"Jeldres C, Sun M, Isbarn H, Lughezzani G, Bud\u00e4us L, Alasker A, Shariat SF, Lattouf JB, Widmer H, Pharand D, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI (2010) A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology 75:315\u2013320. https:\/\/doi.org\/10.1016\/j.urology.2009.10.004","journal-title":"Urology"},{"key":"3239_CR5","doi-asserted-by":"publisher","first-page":"244ra291","DOI":"10.1126\/scitranslmed.3008970","volume":"6","author":"S Rebouissou","year":"2014","unstructured":"Rebouissou S, Bernard-Pierrot I, de Reyni\u00e8s A, Lepage ML, Krucker C, Chapeaublanc E, H\u00e9rault A, Kamoun A, Caillault A, Letouz\u00e9 E, Elarouci N, Neuzillet Y, Denoux Y, Molini\u00e9 V, Vordos D, Laplanche A, Maill\u00e9 P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F (2014) EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 6:244ra291. https:\/\/doi.org\/10.1126\/scitranslmed.3008970","journal-title":"Sci Transl Med"},{"key":"3239_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12964-020-00625-7","volume":"18","author":"AS Zangouei","year":"2020","unstructured":"Zangouei AS, Barjasteh AH, Rahimi HR, Mojarrad M, Moghbeli M (2020) Role of tyrosine kinases in bladder cancer progression: an overview. Cell Commun Signal 18:127. https:\/\/doi.org\/10.1186\/s12964-020-00625-7","journal-title":"Cell Commun Signal"},{"key":"3239_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.juro.2017.10.041","volume":"199","author":"AO Siefker-Radtke","year":"2018","unstructured":"Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC (2018) Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma. J Urol 199:1129\u20131142. https:\/\/doi.org\/10.1016\/j.juro.2017.10.041","journal-title":"J Urol"},{"key":"3239_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11934-018-0851-7","volume":"19","author":"A Tripathi","year":"2018","unstructured":"Tripathi A, Plimack ER (2018) Immunotherapy for urothelial carcinoma: current evidence and future directions. Curr Urol Rep 19:109. https:\/\/doi.org\/10.1007\/s11934-018-0851-7","journal-title":"Curr Urol Rep"},{"key":"3239_CR9","doi-asserted-by":"publisher","unstructured":"Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Takao T, Yamaguchi S, Fushimi H, Yoshimura K, Uemura H, Netto GJ, Nonomura N (2020) Expression of nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21155390","DOI":"10.3390\/ijms21155390"},{"key":"3239_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1590\/S1677-5538.IBJU.2017.0204","volume":"44","author":"RL Favaretto","year":"2018","unstructured":"Favaretto RL, Zequi SC, Oliveira RAR, Santana T, Costa WH, Cunha IW, Guimar\u00e3es GC (2018) Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications. Int Braz J Urol 44:22\u201337. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2017.0204","journal-title":"Int Braz J Urol"},{"key":"3239_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrurol.2017.120","volume":"14","author":"L Stone","year":"2017","unstructured":"Stone L (2017) Immunology: PD-1 and PD-L1 prognostic in UTUC. Nat Rev Urol 14:518. https:\/\/doi.org\/10.1038\/nrurol.2017.120","journal-title":"Nat Rev Urol"},{"key":"3239_CR12","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jfma.2013.11.004","volume":"113","author":"D Fang","year":"2014","unstructured":"Fang D, Xiong GY, Li XS, Chen XP, Zhang L, Yao L, He ZS, Zhou LQ (2014) Pattern and risk factors of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a large Chinese center experience. J Formos Med Assoc 113:820\u2013827. https:\/\/doi.org\/10.1016\/j.jfma.2013.11.004","journal-title":"J Formos Med Assoc"},{"key":"3239_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/00000478-200108000-00013","volume":"25","author":"JK McKenney","year":"2001","unstructured":"McKenney JK, Desai S, Cohen C, Amin MB (2001) Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 25:1074\u20131078. https:\/\/doi.org\/10.1097\/00000478-200108000-00013","journal-title":"Am J Surg Pathol"},{"key":"3239_CR14","first-page":"400","volume":"30","author":"M Asgari","year":"2016","unstructured":"Asgari M, Nabi Maybodi M, Abolhasani M (2016) Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: analysis of CK20, CD44, P53 and Ki67. Med J Islam Repub Iran 30:400","journal-title":"Med J Islam Repub Iran"},{"key":"3239_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s00120-015-3772-9","volume":"54","author":"S Tschirdewahn","year":"2015","unstructured":"Tschirdewahn S, Vom Dorp F (2015) Diagnostics of nonmuscle-invasive urothelial cell carcinoma of the bladder. Urologe A 54:480\u2013483. https:\/\/doi.org\/10.1007\/s00120-015-3772-9","journal-title":"Urologe A"},{"key":"3239_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.path.2013.10.003","volume":"7","author":"AG Zhou","year":"2014","unstructured":"Zhou AG, Hutchinson LM, Cosar EF (2014) Urine cytopathology and ancillary methods. Surg Pathol Clin 7:77\u201388. https:\/\/doi.org\/10.1016\/j.path.2013.10.003","journal-title":"Surg Pathol Clin"},{"key":"3239_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12894-016-0147-5","volume":"16","author":"A Gopalakrishna","year":"2016","unstructured":"Gopalakrishna A, Longo TA, Fantony JJ, Owusu R, Foo WC, Dash R, Inman BA (2016) The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient. BMC Urol 16:30. https:\/\/doi.org\/10.1186\/s12894-016-0147-5","journal-title":"BMC Urol"},{"key":"3239_CR18","first-page":"937","volume":"34","author":"LS Abdullah","year":"2013","unstructured":"Abdullah LS (2013) The value of urine cytology in the diagnosis of bladder cancer. Cytopathological correlation Saudi Med J 34:937\u2013941","journal-title":"Cytopathological correlation Saudi Med J"},{"key":"3239_CR19","doi-asserted-by":"publisher","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","volume":"33","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W (2015) Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 33:66.e25\u201331. https:\/\/doi.org\/10.1016\/j.urolonc.2014.06.008","journal-title":"Urol Oncol"},{"key":"3239_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/1742-6413.149845","volume":"12","author":"S Chang","year":"2015","unstructured":"Chang S, Smith E, Levin M, Rao JY, Moatamed NA (2015) Comparative study of ProEx C immunocytochemistry and UroVysion fluorescent in-situ hybridization assays on urine cytology specimens. Cytojournal 12:2. https:\/\/doi.org\/10.4103\/1742-6413.149845","journal-title":"Cytojournal"},{"key":"3239_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cncy.20026","volume":"117","author":"PS Sullivan","year":"2009","unstructured":"Sullivan PS, Nooraie F, Sanchez H, Hirschowitz S, Levin M, Rao PN, Rao J (2009) Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a \u201csplit-sample\u201d study. Cancer 117:167\u2013173. https:\/\/doi.org\/10.1002\/cncy.20026","journal-title":"Cancer"},{"key":"3239_CR22","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/cncy.21287","volume":"121","author":"E Comploj","year":"2013","unstructured":"Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E, Lodde M, Horninger W, Pycha A (2013) uCyt+\/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol 121:392\u2013397. https:\/\/doi.org\/10.1002\/cncy.21287","journal-title":"Cancer Cytopathol"},{"key":"3239_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cncy.21327","volume":"121","author":"H Dimashkieh","year":"2013","unstructured":"Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J (2013) Evaluation of UroVysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol 121:591\u2013597. https:\/\/doi.org\/10.1002\/cncy.21327","journal-title":"Cancer Cytopathol"},{"key":"3239_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.dnarep.2004.03.001","volume":"3","author":"CC Chini","year":"2004","unstructured":"Chini CC, Chen J (2004) Claspin, a regulator of Chk1 in DNA replication stress pathway. DNA Repair (Amst) 3:1033\u20131037. https:\/\/doi.org\/10.1016\/j.dnarep.2004.03.001","journal-title":"DNA Repair (Amst)"},{"key":"3239_CR25","doi-asserted-by":"publisher","first-page":"30057","DOI":"10.1074\/jbc.M301136200","volume":"278","author":"CC Chini","year":"2003","unstructured":"Chini CC, Chen J (2003) Human claspin is required for replication checkpoint control. J Biol Chem 278:30057\u201330062. https:\/\/doi.org\/10.1074\/jbc.M301136200","journal-title":"J Biol Chem"},{"key":"3239_CR26","doi-asserted-by":"publisher","first-page":"46782","DOI":"10.1074\/jbc.M304551200","volume":"278","author":"SY Jeong","year":"2003","unstructured":"Jeong SY, Kumagai A, Lee J, Dunphy WG (2003) Phosphorylated claspin interacts with a phosphate-binding site in the kinase domain of Chk1 during ATR-mediated activation. J Biol Chem 278:46782\u201346788. https:\/\/doi.org\/10.1074\/jbc.M304551200","journal-title":"J Biol Chem"},{"key":"3239_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1479-5876-10-132","volume":"10","author":"M Benevolo","year":"2012","unstructured":"Benevolo M, Musio A, Vocaturo A, Don\u00e0 MG, Rollo F, Terrenato I, Carosi M, Pescarmona E, Vocaturo G, Mottolese M (2012) Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix. J Transl Med 10:132. https:\/\/doi.org\/10.1186\/1479-5876-10-132","journal-title":"J Transl Med"},{"key":"3239_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41467-019-08886-8","volume":"10","author":"JN Bianco","year":"2019","unstructured":"Bianco JN, Bergoglio V, Lin YL, Pillaire MJ, Schmitz AL, Gilhodes J, Lusque A, Mazi\u00e8res J, Lacroix-Triki M, Roumeliotis TI, Choudhary J, Moreaux J, Hoffmann JS, Tourri\u00e8re H, Pasero P (2019) Overexpression of claspin and timeless protects cancer cells from replication stress in a checkpoint-independent manner. Nat Commun 10:910. https:\/\/doi.org\/10.1038\/s41467-019-08886-8","journal-title":"Nat Commun"},{"key":"3239_CR29","doi-asserted-by":"publisher","first-page":"17512","DOI":"10.18632\/oncotarget.24776","volume":"9","author":"F Ito","year":"2018","unstructured":"Ito F, Yoshimoto C, Yamada Y, Sudo T, Kobayashi H (2018) The HNF-1\u03b2-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma. Oncotarget 9:17512\u201317522. https:\/\/doi.org\/10.18632\/oncotarget.24776","journal-title":"Oncotarget"},{"key":"3239_CR30","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.1073\/pnas.0401847101","volume":"101","author":"SY Lin","year":"2004","unstructured":"Lin SY, Li K, Stewart GS, Elledge SJ (2004) Human claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc Natl Acad Sci U S A 101:6484\u20136489. https:\/\/doi.org\/10.1073\/pnas.0401847101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3239_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/path.2095","volume":"211","author":"K Tsimaratou","year":"2007","unstructured":"Tsimaratou K, Kletsas D, Kastrinakis NG, Tsantoulis PK, Evangelou K, Sideridou M, Liontos M, Poulias I, Venere M, Salmas M, Kittas C, Halazonetis TD, Gorgoulis VG (2007) Evaluation of claspin as a proliferation marker in human cancer and normal tissues. J Pathol 211:331\u2013339. https:\/\/doi.org\/10.1002\/path.2095","journal-title":"J Pathol"},{"key":"3239_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.humpath.2018.09.001","volume":"84","author":"G Kobayashi","year":"2019","unstructured":"Kobayashi G, Sentani K, Hattori T, Yamamoto Y, Imai T, Sakamoto N, Kuraoka K, Oue N, Sasaki N, Taniyama K, Yasui W (2019) Clinicopathological significance of claspin overexpression and its association with spheroid formation in gastric cancer. Hum Pathol 84:8\u201317. https:\/\/doi.org\/10.1016\/j.humpath.2018.09.001","journal-title":"Hum Pathol"},{"key":"3239_CR33","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/cas.14299","volume":"111","author":"G Kobayashi","year":"2020","unstructured":"Kobayashi G, Sentani K, Babasaki T, Sekino Y, Shigematsu Y, Hayashi T, Oue N, Teishima J, Matsubara A, Sasaki N, Yasui W (2020) Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma. Cancer Sci 111:1020\u20131027. https:\/\/doi.org\/10.1111\/cas.14299","journal-title":"Cancer Sci"},{"key":"3239_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.4103\/0973-1482.126478","volume":"9","author":"J Li","year":"2013","unstructured":"Li J, Lv B, Li X, He Z, Zhou K (2013) Apoptosis-related molecular differences for response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells. J Cancer Res Ther 9:668\u2013671. https:\/\/doi.org\/10.4103\/0973-1482.126478","journal-title":"J Cancer Res Ther"},{"key":"3239_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231936","volume":"15","author":"M Zajac","year":"2020","unstructured":"Zajac M, Ye J, Mukhopadhyay P, Jin X, Ben Y, Antal J, Gupta AK, Rebelatto MC, Williams JA, Walker J (2020) Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS ONE 15:e0231936. https:\/\/doi.org\/10.1371\/journal.pone.0231936","journal-title":"PLoS ONE"},{"key":"3239_CR36","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"key":"3239_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/cas.13121","volume":"108","author":"T Hattori","year":"2017","unstructured":"Hattori T, Sentani K, Naohide O, Sakamoto N, Yasui W (2017) Clinicopathological significance of SPC18 in colorectal cancer: SPC18 participates in tumor progression. Cancer Sci 108:143\u2013150. https:\/\/doi.org\/10.1111\/cas.13121","journal-title":"Cancer Sci"},{"key":"3239_CR38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa CB, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Weinstein JN, Kwiatkowski DJ, Lerner SP, Network TR (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540-556.e525. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007","journal-title":"Cell"},{"key":"3239_CR39","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avi\u00f1a H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Do\u00f1ate F, Stover DR (2016) Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76:3003\u20133013. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313","journal-title":"Cancer Res"},{"key":"3239_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"P Seshacharyulu","year":"2012","unstructured":"Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15\u201331. https:\/\/doi.org\/10.1517\/14728222.2011.648617","journal-title":"Expert Opin Ther Targets"},{"key":"3239_CR41","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/s41598-019-38575-x","volume":"9","author":"MR Siddiqui","year":"2019","unstructured":"Siddiqui MR, Railkar R, Sanford T, Crooks DR, Eckhaus MA, Haines D, Choyke PL, Kobayashi H, Agarwal PK (2019) Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) expressing bladder cancer using combination photoimmunotherapy (PIT). Sci Rep 9:2084. https:\/\/doi.org\/10.1038\/s41598-019-38575-x","journal-title":"Sci Rep"},{"key":"3239_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-017-1986-y","volume":"66","author":"R Okita","year":"2017","unstructured":"Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M (2017) PD-L1 overexpression is partially regulated by EGFR\/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol Immunother 66:865\u2013876. https:\/\/doi.org\/10.1007\/s00262-017-1986-y","journal-title":"Cancer Immunol Immunother"},{"key":"3239_CR43","doi-asserted-by":"publisher","unstructured":"Padmanabhan R, Kheraldine HS, Meskin N, Vranic S, Al Moustafa AE (2020) Crosstalk between HER2 and PD-1\/PD-L1 in breast cancer: from clinical applications to mathematical models. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12030636","DOI":"10.3390\/cancers12030636"},{"key":"3239_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12885-019-5364-3","volume":"19","author":"M Chen","year":"2019","unstructured":"Chen M, Sharma A, Lin Y, Wu Y, He Q, Gu Y, Xu ZP, Monteiro M, Gu W (2019) Insulin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells. BMC Cancer 19:153. https:\/\/doi.org\/10.1186\/s12885-019-5364-3","journal-title":"BMC Cancer"},{"key":"3239_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/01.MP.0000056628.38714.5D","volume":"16","author":"C Mallofr\u00e9","year":"2003","unstructured":"Mallofr\u00e9 C, Castillo M, Morente V, Sol\u00e9 M (2003) Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 16:187\u2013191. https:\/\/doi.org\/10.1097\/01.MP.0000056628.38714.5D","journal-title":"Mod Pathol"},{"key":"3239_CR46","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/cyt.12332","volume":"27","author":"M Courtade-Sa\u00efdi","year":"2016","unstructured":"Courtade-Sa\u00efdi M, Aziza J, d\u2019Aure D, B\u00e9rard E, Evrard S, Basset C, Lacoste-Collin L (2016) Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology. Cytopathology 27:456\u2013464. https:\/\/doi.org\/10.1111\/cyt.12332","journal-title":"Cytopathology"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03239-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-021-03239-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-021-03239-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T12:30:41Z","timestamp":1649334641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-021-03239-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3239"],"URL":"https:\/\/doi.org\/10.1007\/s00428-021-03239-7","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A statement on ethics approval and consent is in sect. \u201c.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the final version of the manuscript and have given their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}